Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

t fully controlled despite treatment with one or two other antiepileptic drugs. The third study is a randomized, double-blind, placebo-controlled trial with flexible dosing designed to evaluate the safety and tolerability of brivaracetam in patients with uncontrolled partial onset or primary generalized seizures. First results of these studies are expected in mid 2009.

About Brivaracetam: Brivaracetam has distinct pharmacological differences as well as having some structural similarity to the AED Keppra(R) (levetiracetam). In preclinical studies brivaracetam was shown to have a 10- fold higher affinity for synaptic vesicle protein 2A (SV2A) than Keppra(R). Brivaracetam also has inhibitory activity at neuronal voltage-dependent sodium channels whose abnormal function is understood to contribute to electrical discharges associated with seizures. These differences may explain brivaracetam's antiepileptic activity, clinical efficacy and tolerability.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting more than 2.5 million Americans regardless of race, age or sex. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or have significant adverse side effects secondary to medication, highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the U.S.: Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in JME
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The world ... and capacity are intersecting to create new opportunities ... the opening speaker at WesternU's 34th annual Commencement ... Gov. Gavin Newsom, a former San Francisco mayor ... speaker at the graduation ceremony for WesternU's colleges ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... Power Systems is proud to announce the ... season. Drobeck is in his second year of racing in ... the Missoula Fire Department in Missoula, MT. He entered the ... During his career, he has had 15 1st Place finishes. ... 10 finishes in all seven of his 2014 races, including ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Scientists at the ,University of North Carolina at Chapel ... plays a central role in the formation of new blood ... new blood vessel formation, or angiogenesis, is seriously impaired without ... 2011 in the journal Blood , was led by ...
... prevention trial that has been evaluating two antiretroviral (ARV)-based approaches ... daily use of one of two different ARV tablets or ... The decision to discontinue use of the gel, which contains ... study data concluded tenofovir gel was not effective in preventing ...
... -- Patients hospitalized for autoimmune disorders, like rheumatoid arthritis ... life-threatening pulmonary embolism, a clot in a main artery of ... 25 in The Lancet , researchers warned that steps ... to the hospital for autoimmune diseases. , , In conducting ...
... CHICAGO By combining conventional medical imaging with some ... blockbusters, researchers are offering new hope to victims of ... human face transplantation, led by Darren M. Smith, M.D., ... Center (UPMC), were presented today at the annual meeting ...
... News) -- Racism is similar to trauma in how ... the United States, a new analysis finds. An ... 18,000 black adults concluded that there are common responses ... that is expressed as physical pain), interpersonal sensitivity and ...
... should be able to choose where they give birth, concludes ... first-time mums who opt for a home birth are at ... low in all birth settings. The researchers say their ... pregnancies a choice of birth setting" and will enable women ...
Cached Medicine News:Health News:Cell molecule identified as central player in the formation of new blood vessels 2Health News:Cell molecule identified as central player in the formation of new blood vessels 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 2Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 4Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 5Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 6Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 7Health News:Autoimmune Woes May Raise Risk for Lung Clots 2Health News:Integrated 3-D imaging facilitates human face transplantation 2Health News:Integrated 3-D imaging facilitates human face transplantation 3Health News:Pregnant women at low risk of complications can safely be offered a choice of where to give birth 2
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... , May 22, 2015 According ... Market by Product (Consumables, Instruments, Services), by Test Type ... Chromatography, Flow Cytometry), by End Users - Global Forecast ... Market is expected to reach $736.85 Million by 2020 ... of 10.25%. Browse 71 market data ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... research at SRI International, scientists evaluating new drug targets against ... that could rapidly eliminate infections and potentially shorten treatment time. ... B, found in bacteria that cause TB infections. ... A and gyrase B. Although gyrase A is often the ...
... 29, 2011   Acuo Technologies ® ... for intelligent medical image lifecycle management and data ... has selected the Universal Clinical Platform (UCP3) ... UCP3 will replace Fairview,s existing PACS archives while ...
Cached Medicine Technology:SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 3
Stainless steel bone clamp....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Straight double action bone cutting rongeur....
Beuse Zygomatic Arch Awl with slightly curved tip....
Medicine Products: